Natera (NTRA) experienced a 5.36% decline in its stock price on Friday, closing at $186.36, despite receiving FDA approval for its Signatera CDx test as a companion diagnostic for Genentech's Tecentriq (atezolizumab) in muscle-invasive bladder cancer. The broader Nasdaq Composite fell 1.54% on the same day, adding to the pressure on growth-oriented diagnostics stocks.
FDA Approval Details
The U.S. Food and Drug Administration cleared Signatera CDx for use in adults with muscle-invasive bladder cancer who have molecular residual disease (MRD) after surgical removal of the bladder. The test helps identify patients with circulating tumor DNA (ctDNA) who may benefit from treatment with Tecentriq. The FDA cited results from the IMvigor011 trial, which showed a median disease-free survival of 9.9 months for patients receiving atezolizumab compared to 4.8 months for placebo. Median overall survival was 32.8 months with the drug versus 21.1 months for placebo.
Market Reaction
Despite the regulatory milestone, Natera shares ended the week below the prior Friday's close of $194.24, hitting a one-month low of $184.81 during Friday's session. The stock had closed at $196.91 on Thursday before the FDA announcement. Analysts noted that some traders may have been reducing exposure to healthcare growth stocks ahead of the weekend, overshadowing the positive news.
Earnings and Outlook
Natera recently reported first-quarter 2026 revenue of $696.6 million, a 38.8% year-over-year increase, and processed over 1 million tests during the quarter. The company raised its full-year 2026 revenue guidance to a range of $2.74 billion to $2.82 billion. However, net losses widened to $85.1 million from $66.9 million a year ago, reflecting increased spending on research, development, and commercialization.
Industry Context
Competition in the blood-based cancer testing space is intensifying, with Guardant Health and Tempus AI making significant strides. The Wall Street Journal recently highlighted MRD testing as a key focus for investors, with Natera's Signatera considered central to the company's growth narrative. However, the approval alone may not immediately translate into rapid reimbursement, physician adoption, or margin expansion, especially given the stock's recent run-up.
Expert Commentary
Professor Thomas Powles, lead investigator of the IMvigor011 trial and chair of Barts Cancer Centre, stated that the approval demonstrates MRD's ability to answer questions about "when to treat, whom to treat." Solomon Moshkevich, president of clinical diagnostics at Natera, called the FDA decision "a major milestone" that "solidifies Signatera MRD" in muscle-invasive bladder cancer. Genentech Chief Medical Officer Levi Garraway noted that pairing Tecentriq with MRD testing enables "more precise identification" of patients and may allow others to "safely avoid unnecessary treatment."
Technical Outlook
Traders face a potentially choppy setup on Monday. If the stock holds above Friday's low of $184.81, buyers may step in. A return to the $194-$200 range would bring it back to last week's trading band. However, if that low breaks and the Nasdaq or biotech sector continues to slide, further profit-taking could occur ahead of a full repricing of the FDA catalyst.
